Answers are grounded in this paper and cite their sources.
Peroxisome proliferator-activated receptor-gamma (PPARgamma) exerts multiple functions in determination of cell fate, tissue metabolism, and host immunity. Two synthetic PPARgamma ligands (rosiglitazone and pioglitazone) were approved for the therapy of type-2 diabetes mellitus and are expected to serve as novel cures for inflammatory diseases and cancer. However, PPARgamma and its ligands exhibit a janus-face behaviour as tumor modulators in various systems, resulting in either tumor suppression or tumor promotion. This may be in part due to signaling crosstalk to the mitogen-activated protein kinase (MAPK) cascades. The genomic activity of PPARgamma is modulated, in addition to ligand binding, by phosphorylation of a serine residue by MAPKs, such as extracellular signal-regulated protein kinases-1/2 (ERK-1/2), or by nucleocytoplasmic compartmentalization through the ERK activators MAPK kinases-1/2 (MEK-1/2). PPARgamma ligands themselves activate the ERK cascade through nongenomic and often PPARgamma-independent signaling. In the current review, we discuss the molecular mechanisms and physiological implications of the crosstalk of PPARgamma with MEK-ERK signaling and its potential as a novel drug target for cancer therapy in patients.
No takes yet. Share an insight, caveat, or question.
Burgermeister et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: